OPZELURA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPZELURA (OPZELURA).
Topical Janus kinase (JAK) inhibitor; inhibits JAK1 and JAK2, leading to decreased STAT phosphorylation and modulation of inflammatory cytokine production.
| Metabolism | Hepatic metabolism primarily via CYP3A4 and CYP2C9. |
| Excretion | Approximately 70% of the dose is excreted in feces (as unchanged drug and metabolites), and approximately 30% is excreted in urine (as unchanged drug and metabolites). |
| Half-life | Approximately 4.9 hours (range 3.2–7.6 hours) in healthy subjects; clinical impact: supports twice-daily dosing. |
| Protein binding | Approximately 99.7% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Approximately 3.6 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Topical: Systemic absorption is minimal but measurable; bioavailability not applicable due to topical route; oral bioavailability (if ingested) is approximately 50% (not clinically relevant). |
| Onset of Action | Topical: Improvement in pruritus can be observed within 2 weeks; significant reduction in Eczema Area and Severity Index (EASI) scores by 4 weeks. |
| Duration of Action | Duration of action: 12 hours; with twice-daily application, clinical improvement is sustained; note: continuous use is required for maintenance. |
| Molecular Weight | 306.37 |
1.5% topical cream applied twice daily to affected areas; not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (eGFR <30 mL/min). |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment; not recommended for severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients <12 years have not been established; for ≥12 years, same as adult dosing. |
| Geriatric use | No specific dose adjustment recommended; limited data in patients ≥65 years; use with caution due to potential increased sensitivity. |
| 1st trimester | Avoid use. Animal studies show teratogenicity and embryotoxicity. No adequate human data. |
| 2nd trimester | Avoid use. Potential fetal harm based on animal data. |
| 3rd trimester | Avoid use. Potential fetal harm based on animal data. |
Clinical note
Comprehensive clinical and safety monograph for OPZELURA (OPZELURA).
| Placental transfer | Animal studies indicate that ruxolitinib crosses the placenta and is transferred to the fetus. Human data are not available. |
| Breastfeeding | Not recommended. It is unknown if ruxolitinib is excreted in human milk. Due to potential serious adverse reactions in the nursing infant, advise patients not to breastfeed during treatment and for 2 weeks after the final dose. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis with use of JAK inhibitors. However, a boxed warning specific to topical ruxolitinib may not be explicitly listed; the boxed warning for systemic JAK inhibitors is typically not included for topical forms, but the FDA label may include serious warnings.
| Serious Effects |
Hypersensitivity to ruxolitinib or any excipients
| Precautions | Serious infections, including bacterial, fungal, viral, and opportunistic infections; malignancy; thrombosis; major adverse cardiovascular events; increase in lipid parameters; treatment discontinuation for serious adverse reactions; application site reactions; use in immunocompromised patients; use with other JAK inhibitors or potent immunosuppressants. |
| Food/Dietary | No specific food interactions have been reported with topical ruxolitinib. Systemic absorption is minimal, but it is prudent to avoid grapefruit juice and other strong CYP3A4 modulators (e.g., St. John's wort) as they may theoretically affect systemic levels, though no clinical data support this. Maintain a balanced diet; no dietary restrictions required. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | In animal studies, ruxolitinib (active ingredient of OPZELURA) was associated with increased post-implantation loss, reduced fetal body weight, and skeletal variations at systemic exposures comparable to the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Based on animal data, there is a potential risk to the fetus, including developmental toxicity. Use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus. Women of reproductive potential should be advised to use effective contraception during treatment and for at least 4 weeks after the last dose. |
| Fetal Monitoring | Monitor complete blood counts (CBC) with differential at baseline and periodically thereafter, as ruxolitinib can cause thrombocytopenia, anemia, and neutropenia. In pregnant women, monitor fetal growth and development with appropriate ultrasound examinations. Assess for signs of infection, as ruxolitinib may increase the risk of infections. |
| Fertility Effects | In animal studies, ruxolitinib did not impair male or female fertility at systemic exposures up to approximately 5.5 times the maximum human exposure. However, based on its mechanism of action (JAK inhibition), there is a theoretical potential for effects on reproductive tissues. Human fertility data are not available. |
| Clinical Pearls | OPZELURA (ruxolitinib) is a topical Janus kinase (JAK) inhibitor indicated for atopic dermatitis and nonsegmental vitiligo. Do not use with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants. Apply to ≤20% body surface area (BSA); thin layer up to twice daily. Avoid application to infected areas. Monitor for thrombocytopenia, neutropenia, and elevated liver enzymes; complete blood count (CBC) and liver function tests (LFTs) recommended at baseline and periodically. Use with caution in patients with active serious infections, malignancies, or thrombosis. Avoid live vaccines during treatment. Pregnancy category C; no data on breastfeeding. |
| Patient Advice | Apply a thin layer only to affected areas of skin, up to twice daily, using no more than 1 fingertip unit per 10% BSA. · Wash hands after application unless treating hands. · Avoid use on more than 20% of your body surface area. · Do not apply to eyes, mouth, or vagina, or to areas with open cuts, wounds, or infections. · Do not cover treated areas with bandages or dressings unless instructed by your doctor. · Stop use and contact your doctor if you develop signs of infection, bruising, bleeding, or unusual tiredness. · Avoid live vaccines during treatment and for 4 weeks after stopping therapy. · Store at room temperature, keep tube tightly closed, and avoid exposure to heat or direct sunlight. · Treatment duration for atopic dermatitis: up to 8 weeks; for vitiligo: up to 24 weeks, reassess periodically. · Inform your doctor about all medications you take, including other topical products, especially other JAK inhibitors or immunosuppressants. · Breastfeeding is not recommended during treatment and for 1 week after the last dose. · Do not smoke or have other cardiovascular risk factors without consulting your doctor due to increased thrombosis risk. · Attend all scheduled blood tests to monitor for side effects. |